Andere talen Disc Medicine, Inc.

Aandelen

IRON

US2546041011

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
29,79 ^USD	+2,72%		+8,13%	-48,42%

08/04	DISC MEDICINE, INC. : Stifel Nicolaus geeft koopadvies	ZM
02/04	DISC MEDICINE, INC. : Leerink Partners ontvangt een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

North American Morning Briefing : Stocks Seen -2-	02/04
Top Midday Decliners	01/04
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	01/04
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)	01/04
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	01/04
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	21/03
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024	06/03
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer	26/02
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer	26/02
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer	26/02
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	20/02
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	20/02
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	20/02
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation	09/02
Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment	09/02
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	09/02
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	09/02
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer	07/02
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer	07/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Disc Medicine, Inc.

Aandelen

IRON

US2546041011

Andere talen

Filters